TrialCancer immunology, immunotherapy : CII2015

Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study.

Riccardo Danielli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.